Literature DB >> 18024403

Tricuspid regurgitant jet velocity is associated with hemolysis in children and young adults with sickle cell disease evaluated for pulmonary hypertension.

Robert I Liem1, Luciana T Young, Alexis A Thompson.   

Abstract

Tricuspid regurgitant jet velocity (TRJV) >or= 2.5 m/sec. on echocardiography is a surrogate marker for pulmonary hypertension (PHT) in adults with sickle cell disease (SCD). We prospectively examined the relationship between TRJV and laboratory markers of hemolysis in 51 children and young adults with SCD at baseline. We found significant correlations between TRJV and lactate dehydrogenase (LDH), hemoglobin (Hb), reticulocyte count (retic) and aspartate aminotransferase (AST). LDH, retic and AST were significantly higher and Hb was lower in subjects with TRJV >or= 2.5 m/sec. We conclude that hemolysis significantly contributes to TRJV elevation in children and young adults with SCD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024403     DOI: 10.3324/haematol.11576

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  14 in total

Review 1.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

2.  Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective.

Authors:  Roberto F Machado; Mark T Gladwin
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

3.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

Review 4.  Intravascular hemolysis and the pathophysiology of sickle cell disease.

Authors:  Gregory J Kato; Martin H Steinberg; Mark T Gladwin
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

5.  Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia.

Authors:  Charles T Quinn; Eric P Smith; Shahriar Arbabi; Paramjit K Khera; Christopher J Lindsell; Omar Niss; Clinton H Joiner; Robert S Franco; Robert M Cohen
Journal:  Am J Hematol       Date:  2016-11-08       Impact factor: 10.047

Review 6.  Pulmonary hypertension in sickle cell disease: relevance to children.

Authors:  Gregory J Kato; Onyinye C Onyekwere; Mark T Gladwin
Journal:  Pediatr Hematol Oncol       Date:  2007 Apr-May       Impact factor: 1.969

Review 7.  Pulmonary arterial hypertension in children: a medical update.

Authors:  Erika B Rosenzweig; Robyn J Barst
Journal:  Indian J Pediatr       Date:  2009-04-18       Impact factor: 1.967

Review 8.  Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders.

Authors:  Roberto F Machado; Harrison W Farber
Journal:  Clin Chest Med       Date:  2013-10-17       Impact factor: 2.878

9.  Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Authors:  Victor R Gordeuk; Andrew Campbell; Sohail Rana; Mehdi Nouraie; Xiaomei Niu; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; Onyinye Onyekwere; Tatiana Ammosova; Sergei Nekhai; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

10.  Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease.

Authors:  Xiaomei Niu; Mehdi Nouraie; Andrew Campbell; Sohail Rana; Caterina P Minniti; Craig Sable; Deepika Darbari; Niti Dham; N Scott Reading; Josef T Prchal; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Victor R Gordeuk
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.